Big Pharma’s Patent Abuses Are Fueling the Drug Pricing Crisis
The latest in news from I-MAK experts.
For press inquiries, please contact simon@i-mak.org.
June 2025: Still Overpatented, Still Overpriced
May 2025: Merck’s Scheme to Product Hop Keytruda
How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
How Pharma and Its Consultants Abuse the Patent System
March 2025: We Need More Drug Patent Data
Investigating the pharmaceutical industry’s drug patenting practices
Feb 2025: Five Patent Predictions for 2025
Dec 2024: The Year in Patent Reform
Oct 2024: The real legacy of the Hatch-Waxman Act
Mar 2024: Why Current Legislation to Prevent Patent Thickets Are a Good Start — But Not Enough